L&T Technology Services share price fall 5% despite strong revenue growth in Q4 – Should you buy, sell or hold?
Shares of L&T Technology Services (LTTS) plunged nearly 5% to ₹4,255.10 on Thursday despite posting double-digit revenue growth in Q4FY25, as profit declined due to the impact of its recent acquisition.
The company reported a consolidated revenue of ₹2,982.4 crore for the quarter ended March 31, 2025, marking a 12.4% quarter-on-quarter increase. However, net profit fell 3.5% sequentially to ₹311.1 crore, mainly due to lower operating margins and costs related to the Intelliswift acquisition.
Operating margins shrank to 13.2% from 15.9% in the previous quarter.
Amit Chadha, CEO and MD of LTTS, said, 'We continued our industry-leading QoQ growth momentum with a third straight quarter of sequential growth of 10.7% and delivered 8.9% revenue growth in constant currency in FY25 despite a challenging environment.'
LTTS announced record deal bookings in the March quarter, including one $80 million deal, one $50 million deal, a $30 million deal, a $20 million deal, and three $10 million deals.
Despite this strong deal pipeline, Citi retained its 'Sell' rating on the stock with a revised target price of ₹3,800, down from its previous target of ₹4,105, reflecting concerns around margin pressure and integration-related risks.
Meanwhile, LTTS shares were trading at ₹4,255.10, down 4.98% or ₹222.80 on the NSE, compared to a previous close of ₹4,477.90.
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
L&T Energy GreenTech partners with ITOCHU to develop 300 KTPA green ammonia project in Gujarat
L&T Energy GreenTech Ltd (LTEG), a wholly-owned subsidiary of Larsen & Toubro (L&T), has joined hands with Japan's ITOCHU Corporation to develop and commercialize a 300 KTPA green ammonia project at Kandla, Gujarat. This strategic partnership marks a significant milestone in promoting sustainable energy solutions for the maritime sector. Under the Joint Development Agreement (JDA), LTEG and ITOCHU will collaborate on building the green ammonia plant, with ITOCHU planning to offtake the ammonia for bunkering applications in Singapore. This initiative aligns with both companies' commitment to decarbonization and low-carbon marine fuels. Last year, L&T acquired a large land parcel at Kandla to strengthen its footprint in green hydrogen and green ammonia projects. The new collaboration further supports LTEG's vision to create a comprehensive presence across the green energy value chain while complementing ITOCHU's efforts to promote zero-emission ammonia-based fuels. India's vast renewable resources and competitive electricity costs make it an ideal hub for green hydrogen production. The country's National Green Hydrogen Mission aims to achieve a production capacity of at least 5 MMTPA by 2030, attracting investments exceeding USD 100 billion. This initiative is poised to drive industrial innovation, generate green jobs, and enhance India's energy security. With the LTEG-ITOCHU partnership, India takes another step toward becoming a global leader in green hydrogen and sustainable maritime fuel solutions, contributing to a cleaner, low-carbon future. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
3 hours ago
- Business Upturn
Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market
Mumbai-based Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market Rivaroxaban Tablets USP in strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg. The product is the generic equivalent of Janssen Pharmaceuticals' blockbuster anticoagulant, Xarelto, and will be manufactured at Indoco's Verna, Goa facility. The approved Rivaroxaban tablets are bioequivalent and therapeutically equivalent to Xarelto and are indicated for the treatment of venous thromboembolism (VTE). This approval marks another milestone in Indoco's push into the US generics market, one of the most lucrative pharmaceutical markets globally. Commenting on the development, Indoco Remedies' Managing Director Aditi Panandikar said, 'Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.' Indoco Remedies is a fully integrated, research-driven pharmaceutical company with a global footprint, generating over 106 million prescriptions annually in India alone. The company operates 11 manufacturing facilities — seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs) — all of which are approved by top global regulatory agencies including the USFDA and UK-MHRA. With a turnover of $180 million and a workforce of more than 6,000 employees, Indoco is known for popular domestic brands such as Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, and Cital. Internationally, the company partners with large generics players to expand its market reach across multiple geographies. The latest USFDA approval strengthens Indoco's product portfolio in the regulated market and could open up significant revenue opportunities as Rivaroxaban continues to be a widely prescribed oral anticoagulant in the US. Disclaimer: This news article is for informational purposes only and does not constitute investment advice. Investors should consult a qualified financial advisor before making investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
3 hours ago
- Business Upturn
Why are Indoco Remedies shares up 2% today? Explained
By Aditya Bhagchandani Published on August 13, 2025, 10:05 IST Indoco Remedies Ltd shares climbed over 2% to ₹299.30 in morning trade on Tuesday after the company announced it has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Rivaroxaban tablets, a generic version of Bayer's blockbuster anticoagulant Xarelto. The approval covers multiple dosage strengths — 2.5 mg, 10 mg, 15 mg, and 20 mg — positioning Indoco to tap into the lucrative US market for blood thinners, which has significant demand due to rising cardiovascular cases. Industry data shows Rivaroxaban sales in the US crossed $2 billion in recent years. Indoco said the launch will be executed through its marketing partner in the US, adding that this development strengthens its complex generics portfolio and enhances its revenue visibility in the American market. The stock's rally reflects investor optimism about the earnings potential from this launch, given that US generics typically offer higher margins than domestic formulations. Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investing in equities involves risks. Please consult a certified financial advisor before making any investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
